Jeff Martin
Stock Analyst at Roth Capital
(4.26)
# 380
Out of 5,163 analysts
67
Total ratings
57.14%
Success rate
14.79%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBSI Barrett Business Services | Maintains: Buy | $54 → $42 | $27.50 | +52.73% | 6 | Feb 26, 2026 | |
| OSIS OSI Systems | Maintains: Buy | $292 → $295 | $270.92 | +8.89% | 18 | Jan 30, 2026 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $45 → $50 | $28.02 | +78.44% | 6 | Dec 9, 2025 | |
| PERI Perion Network | Reiterates: Buy | $14 → $15 | $8.55 | +69.59% | 10 | Nov 13, 2025 | |
| NSP Insperity | Maintains: Buy | $85 → $74 | $20.18 | +266.70% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $11.54 | +133.97% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $3.48 | +43.68% | 1 | May 14, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $6.40 | +40.63% | 1 | Mar 20, 2025 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $13.85 | +116.61% | 6 | Nov 5, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $0.63 | +914,185.71% | 2 | Nov 15, 2017 |
Barrett Business Services
Feb 26, 2026
Maintains: Buy
Price Target: $54 → $42
Current: $27.50
Upside: +52.73%
OSI Systems
Jan 30, 2026
Maintains: Buy
Price Target: $292 → $295
Current: $270.92
Upside: +8.89%
Bowman Consulting Group
Dec 9, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $28.02
Upside: +78.44%
Perion Network
Nov 13, 2025
Reiterates: Buy
Price Target: $14 → $15
Current: $8.55
Upside: +69.59%
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $20.18
Upside: +266.70%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $11.54
Upside: +133.97%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $3.48
Upside: +43.68%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $6.40
Upside: +40.63%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $13.85
Upside: +116.61%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $0.63
Upside: +914,185.71%